Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis
| Autor: | Mario Plebani, Antonio G. Secchi, Andrea Leonardi, Franco Borghesan, Antonio Avarello |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Male
Allergy medicine.medical_specialty Cromoglicic acid Radioimmunoassay Gastroenterology Cellular and Molecular Neuroscience Ribonucleases Double-Blind Method Internal medicine Cromolyn Sodium Eosinophil activation Humans Medicine Child Keratoconjunctivitis Conjunctivitis Allergic Oxamic Acid Eosinophil cationic protein Lodoxamide business.industry Blood Proteins Eosinophil Granule Proteins Original articles - Clinical science medicine.disease eye diseases Sensory Systems Ophthalmology Tears Immunology Female sense organs business Vernal keratoconjunctivitis Biomarkers medicine.drug |
| Zdroj: | British Journal of Ophthalmology. 81:23-26 |
| ISSN: | 0007-1161 |
| Popis: | AIM—To validate the use of tear eosinophil cationic protein (ECP) as a marker for eosinophil activation, and its pharmacological modulation, in addition to evaluating the efficacy of lodoxamide and sodium cromoglycate in the treatment of vernal keratoconjunctivitis (VKC). METHODS—Tears were collected from 30 patients affected by active mild to moderate VKC before and after therapy with disodium cromoglycate 4% (DSCG) (n=15) or lodoxamide 0.1% (n=15) for 10 days. Tear cytology and ECP measurement were performed, and ocular signs and symptoms evaluated. RESULTS—While statistically significant changes did not occur after DSCG therapy, mean tear ECP increased from 343 (SD 363) µg/l to 571 (777) µg/l due to marked elevation in six eyes. The clinical score in DSCG eyes did not improve. After lodoxamide therapy, both clinical signs and symptoms, and tear ECP levels (560 (756) µg/l to 241 (376) µg/l) decreased significantly (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|